

THE GUT-LIVER AXIS

07-09 JUNE 2018

LEUVEN, BELGIUM

SCIENTIFIC ORGANISING COMMITTEE

Maria Rescigno, *Milan, Italy*

Andrea De Gottardi, *Berne, Switzerland*

Agustin Albillos, *Madrid, Spain*

PRELIMINARY* PROGRAMME

DAY I – 07 June 2018

13:45 – 14:00 **Welcome message**
Agustin Albillos, Maria Rescigno. Andrea de Gottardi

14:00 – 14:15 **Opening Remarks**
TBC

14:15 – 15:00 **State-of-the-art-lecture**
The basis of the gut liver axis
TBC

Session I: From single components to integrated signaling
Chairs: Maria Rescigno and Andrew Macpherson

15:00 - 15:25 **Structure and function of the intestinal barrier**
Maria Rescigno, *Italy*

15:25 – 15:50 **Enteroendocrine and cytokine signaling**
TBC

15:50 – 16:15 **Circulation and homing of immune cells**
David Adams, *United Kingdom*

16:15 – 16:40 **Bile acid signaling in the gut-liver axis**
TBC

16:40 – 17:10 *Poster session and coffee break*

*Subject to change

Session 2: The impact of intestinal alterations for the pathophysiology of liver diseases
Chairs: Andre Franke and Jeroen Raes

- 17:10 – 17:35** **Disturbances of gut microbiota on liver inflammation and fibrosis**
Bernd Schnabl, *United States*
- 17:35 – 18:00** **Contribution of intestinal inflammation and dysbiosis to cholestatic liver disease**
Johannes Hov, *Norway*
- 18:00 – 18:25** **The gut-liver axis in the control of hepatobiliary malignancies**
Antonio Moschetta, *Italy*
- 18:25 – 18:50** **Liver and gut-derived inflammation in the pathophysiology of ACLF**
Jonel Trebicka, *Germany*
- 18:50 – 19:10** **Industry point of view: Targeting the intestine in gut-liver axis**
TBC
- 19:10 – 20:10** *Poster session and cocktail reception*

DAY 2 – 08 June 2018

Session 3: Lifestyle and exposure contributions to intestinal homeostasis
Chairs: Andrea de Gottardi and Therry Gustot

- 08:30 – 08:55** **Effects of xenobiotics and nutrition on the ecology of intestinal microbiota**
TBC
- 08:55 – 09:20** **Health care exposure and multidrug resistant bacteria infections in cirrhosis**
Pere Ginés, *Spain*
- 09:20 – 09:45** **The intestinal mucus and environmental exposures**
TBC
- 09:45 – 10:05** **Industry point of view: Antibiotics to modulate the gut-liver-axis**
TBC

*Subject to change

10:05 – 11:00	Abstract session
11:00 – 11:30	<i>Poster Session and Coffee Break</i>
Session 4: The impact of liver disease on the gut-liver axis Chairs: Agustín Albillos and Rajiv Jalan	
11:30 - 11:55	Effects of NAFLD on the gut microbiota and lipid metabolism <i>Patrice Cani, Belgium</i>
11:55 – 12:20	Interaction between intestine and liver in alcoholic liver disease <i>Ramón Bataller, United States</i>
12: 20 – 12:45	Intestinal barrier failure in cirrhosis: impact on complications <i>Agustín Albillos, Spain</i>
12:45 – 13:05	Industry point of view: FXR agonists or antagonists TBC
13:10 – 14:15	<i>Lunch break and ePosters session</i>
Session 5: Debate session: the optimal “toolbox” to address the gut-liver axis. Chairs: Bernd Schnabl and TBC	
14:30 – 14:50	Gnotobiotic animal models TBC
14:50 – 15:10	Assessment of intestinal permeability and translocation TBC
15:10 – 15:30	Endoscopy and imaging tools <i>Reiner Wiest, Switzerland</i>
15:30 – 15:50	Industry point of view: Diagnostic technology company TBC
15:50 – 16:30	<i>ePoster Session and coffee break</i>
16:30 – 17:15	State-of-the-art lecture

*Subject to change

Host control of the gut microbiota: The case of liver disease
TBC

Session 6: Intervention – gut - centric aspects
Chairs: TBC and David Adams

17:15 – 17:40	Personalized nutrition TBC
17:40 – 18:05	Next generation probiotics TBC
18:05 – 18:30	Fecal transplantation in cirrhosis Jasmohan Bajaj, <i>United States</i>
18:30 – 18:55	Impact of gut microbiome in therapy: lessons from oncology TBC
18:55 – 19:20	Nanoporous carbon adsorbent to modify liver disease TBC
19:20 – 19:35	Industry point of view: Impact of ingested bacteria on human gut microbiota TBC
20:00 – 22:00	<i>Dinner</i>

DAY 3 – 09 June 2018

Session 7: Intervention – liver-centric aspects
Chairs: Massimo Pinzani and Frederik Nevens

09:00 – 09:25	Bile acid signaling and the FXR pathway Michael Trauner, <i>Austria</i>
09:25 – 09:50	Modulating the gut-liver axis in cirrhosis and portal hypertension Andrea De Gottardi, <i>Switzerland</i>
09:50 – 10:15	The inflammasome as a target of the gut-liver axis TBC
10:15 – 10:35	Industry point of view: Probiotics in liver disease

*Subject to change

TBC

10:35 – 10:55

Industry point of view: FXR agonists and beyond
TBC

10:55 – 11:30

ePoster session and coffee break

Session 8: Debate: The future of the gut-liver axis in hepatology

Chairs: Agustin Albillos, Maria Rescigno and Andrea De Gottardi

11:30 – 11:50

Unmet technical and methodological needs
TBC

11:50 – 12:10

IO Drug- and xenobiotic metabolism and the gut microbiota
TBC

12:10 – 12:30

Designing clinical trials targeting the gut microbiota
Max Niewdorp, *Netherland*

12:30 – 12:45

Closing remarks
Agustin Albillos, Maria Rescigno, and Andrea De Gottardi

***Subject to change**